Faeth Therapeutics (FTH) Other Non-Current Liabilities (2020 - 2026)

Faeth Therapeutics' (FTH) quarterly Other Non-Current Liabilities came in at $1000.0 in Q1 2026, down 98.51% on a QoQ basis from $67000.0 in Q2 2024.

Faeth Therapeutics (FTH) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends

Faeth Therapeutics (FTH) has 5 years of Other Non-Current Liabilities data on file, last reported at $1000.0 in Q1 2026.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $1000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1000.0 (changed N/A YoY) and the FY2023 annual result came in at $67000.0, changed N/A from the prior year.
Other Non-Current Liabilities slipped to $1000.0 in Q1 2026, from $67000.0 in the prior quarter.
In the past five years, Other Non-Current Liabilities ranged from a high of $72000.0 in Q2 2023 to a low of $1000.0 in Q1 2026.
A 3-year average of $53714.3 and a median of $67000.0 in 2023 frame the typical range for Other Non-Current Liabilities.
The widest YoY moves for Other Non-Current Liabilities: up 100.0% in 2024, down 6.94% in 2024.
Tracing FTH's Other Non-Current Liabilities over 3 years: stood at $67000.0 in 2023, then changed by 0.0% to $67000.0 in 2024, then sank by 98.51% to $1000.0 in 2026.
The last three Other Non-Current Liabilities figures came in at $1000.0 (Q1 2026), $67000.0 (Q2 2024), and $68000.0 (Q1 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.81 Bn	130.96 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.07 Bn	78.08 Bn	3.93 Bn
3	Argenx Se	65.47 Bn	60.29 Bn	1.37 Bn
4	Moderna	55.64 Bn	50.50 Bn	52.00 Mn
5	BeOne Medicines	41.99 Bn	36.89 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.68 Bn	28.37 Bn	992.69 Mn
7	BioNTech SE	27.69 Bn	9.29 Bn	668.28 Mn
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
9	Royalty Pharma	27.36 Bn	26.52 Bn	-
10	Faeth Therapeutics	179.79 Mn	179.79 Mn	-

Download Data